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SW, an 84-year-old African American female,
presented to an outside institution complaining of
dull, intermittent abdominal pain in the anterolateral
and suprapubic regions. Decreased appetite, nausea,
and general weakness accompanied this pain.
Physical exam revealed a soft, non-tender mass in
the left upper quadrant that extended 20cm below
the costal margin. A separate 2cm mass, in the
periumbilical area, was also palpable. A CT scan
(Figure 1) was performed and revealed a large, soft
tissue mass in the left upper quadrant extending from
the gastroesophageal junction to the mid-abdomen.
The mass seemed to originate from the stomach
compressing the stomach medially, and the pancreas
and spleen inferiorly and laterally. The periumbilical
mass was subcutaneous and separate from the
larger mass. A fine needle aspiration and biopsy
of the umbilical mass was diagnosed as a myxoid
chondrosarcoma. No further therapy was given at
that time.
Approximately four months later, the patient
presented to our institution with nausea, abdominal
pain, and increased regurgitation of food. Given the
clinical presentation, radiologic findings, and biopsy
results, the patient was felt to have a primary sarcoma
of the stomach. Since the patient was an appropriate
surgical candidate, she was taken to the operating
room. Upon laparotomy, a large mass, originating
from a pedicle attached to the greater curvature
of the stomach, was observed. The tumor was
adherent to the diaphragm and to the lateral segment
of the liver. No invasion of any other adjacent
structures was observed. The periumbilical mass
appeared to be a portion of the original tumor that
had become incarcerated in an umbilical hernia
defect that had fractured away from the dominant
lesion.
On gross pathologic examination, a 7012 gram,
multinodular, cerebreform mass, was observed to be
arising from within the wall of the greater curvature
of the stomach. This mass extended from near
the gastroesophageal junction to the pyloris. The
tumor showed expansive intra-abdominal growth
and involved the omentum and anterior abdominal
wall. Sectioning showed a heterogeneous, lobulated,
gray-white mass with areas of necrosis, hemorrhage,
and cystic degeneration (Figure 2).
The tumor had a variable histologic appearance.
Portions of the tumor were relatively hypocellular
with a vaguely nodular, but prominent chondroid
matrix. Dispersed within this matrix were discohe-
sive epithelioid cells. Focal areas of myxoid cystic
degeneration were also present. The majority of
the tumor was extremely cellular containing sheets
of epithelioid cells within a chondroid matrix.
Additionally, other areas had more spindle-shaped
cells. These cells showed nuclear palisading and
were aligned in a perivascular distribution. Focally,
these cells formed microcysts. Tumor cell necrosis,
hemorrhage, and high mitotic activity (65/50hpf) was
observed in these spindle cell areas. The differential
diagnosis of this tumor upon H&E staining included
a chondrosarcoma and a gastrointestinal stromal
tumor (Figure 3). S100 staining, which should be
positive in >95% of chondrosarcomas, was negative.
The tumor cells were positive for c-kit (CD-117),
CD-34, CD-99 (mic2), and smooth muscle actin
(SMA) (Figure 3). This staining pattern confirmed
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(GIST).
Discussion
We describe an intraabdominal gastrointestinal
stromal tumor (GIST) arising from the stomach
with chondro-myxoid features, which has not been
previously reported. Its histologic appearance was
originally felt to represent a chondrosarcoma, which
does not arise from the gastric wall. We originally
encountered this lesion prior to the utilization of
CD99 and CD117 immunohistochemical staining
for GIST tumors. Thus, the emergence of the
Figure 1. Axial CT scan image showing the obvious large, left upper quadrant mass.
Figure 2. Gross pathologic specimen showing heterogeneous, lobulated mass with areas of necrosis, hemorrhage, and cystic degeneration.
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variant of GIST.
GIST was once a term applied to a diverse group
of neoplasms. Historically, this term was used to
describe all mesenchymal tumors of the gastrointest-
inal (GI) tract. Since this term was applied to a group
of tumors instead of just one, there was a consider-
able debate in regards to this ‘‘single tumor’s’’
histogenesis. It is now clear that the term GIST
refers only to those tumors that arise from the
interstitial cells of Cajal or their precursors, the
gastrointestinal pacemaker cells [1–3].
Contributing to this historical confusion over the
histogenesis of GIST is their variable light micro-
scopic appearance. The majority of these tumors
are composed of either epithelioid or spindle cells.
A combination of epithelioid and spindle cells can be
present in the same tumor; however, one of these
morphologies usually predominates. The epithelioid
cells have a solid, sheet-like architecture and may
show focal vacuolar change mimicking signet ring
cells. They also may contain peripherally located
hyperchromatic nuclei. The spindle cells may have a
fibrillary or myxoid stroma, form microcysts, become
arranged in fascicles, show nuclear palisading, show
perivascular hyalinization, or contain skenoid fibers
within their stroma.
The immunohistochemical staining pattern of
GIST varies with their location within the gastro-
intestinal tract. Miettinen et al. [4], analyzed 92
c-kit positive (CD117) GIST from the stomach.
Of these tumors, 90% were CD-34 positive, 30%
were smooth muscle actin positive, 3% were desmin
positive, and 2% were S100 positive. These results
confirm the ultrastructural finding that the majority
of GIST exhibit a primitive myoid phenotype.
Recently, CD-99 has been shown to be positive in
89% (24 of 27) of GIST [5]. Therefore, a GIST will
typically be c-kit, CD-34, and CD-99 positive, and
both desmin and S100 negative.
The stroma of GIST may contain hemorrhage,
hyalinization, and myxoid changes. Suster [6]
examined 9 cases of GIST with prominent myxoid
stromal backgrounds. These tumors lacked both the
immunohistochemical and ultrastructural features of
neural or ganglionic differentiation. They exhibited
a primitive mesenchymal phenotype with features of
immature smooth muscle cells. The myxoid changes
seen in these lesions may represent a secondary
non-specific reaction of the stroma to the tumor
cells, may be a degenerative change, or may be
directly produced by the tumor cells themselves.
Although the lesion described in this report also has
an extensive myxoid stroma and a myoid phenotype,
it differs from the lesions that Suster described as it
also has extensive areas of a chondroid stromal
matrix. Therefore, this tumor is a distinctive
morphologic variant of GIST that is important for
physicians to recognize.
Gain-of-function mutations in exon 11 of the c-kit
proto-oncogene and c-kit protein overexpression are
found in GIST [7, 8]. The c-kit gene encodes for
Figure 3. Hematoxylin and Eosin stain showing (a) chondroid areas; (b) low power view epithelioid cells demonstrating more cellular
areas and chondroid areas; (c) high power of mitoses in the spindle cell areas; (d) immunohistochemical stain showing c-kit.
Chondro-myxoid GIST 27a receptor for a growth factor called stem cell factor.
This receptor is a tyrosine kinase that regulates cell
growth and survival. Gain-of-function mutations of
the c-kit gene result in ligand-independent constitu-
tive activation of the tyrosine kinase, which plays a
role in tumor promotion.
The metastatic potential of GIST is influenced by
tumor location as well as by pathologic criteria.
Gastric tumors, by virtue of their location, have the
best prognosis. The tumors are best divided into
groups with differing risks for aggressive behavior.
Morphologic criteria for high risk for aggressive
behavior include lesions greater than 5cm with
mitotic rates of greater than 5/50 high power fields
or any tumor greater than 10cm or any size with a
mitotic rate greater than 10/50 high power fields [9].
Stromal tumors with a size less than 2cm and less
than 5 mitoses per 50 high power fields have a very
low risk for aggressive behavior, and tumors with a
size less than 5cm and a mitotic rate of 6–10/50
high power fields or a size between 5 and 10cm and
a mitotic rate of less than 5per 50 high power fields
are considered intermediate risk for aggressive
behavior.
It should be noted that a GIST, although having a
high risk for aggressive behavior, may behave
indolently. On the other hand, a tumor diagnosed
as a GIST with low risk for aggressive behavior may
recur and metastasize. It still has a risk, albeit low,
of metastasizing.
Primary gastrointestinal mesenchymal tumors that
differentiate along myoid, neural, and ganglionic
lines have been shown to have variable biologic
behavior. For example, in the case of a GIST with
a myxoid matrix, the differential diagnosis includes
schwannoma, which behaves indolently, and gastro-
intestinal autonomic nerve tumors, which are known
for their aggressive clinical course. GIST with a
myxoid matrix may behave either indolently or
aggressively (as outlined above). It is important
to differentiate among these tumors since GIST
can be treated effectively with imatinib mesylate
(STI571), an inhibitor of the c-kit receptor tyrosine
kinase [10–13].
Conclusion
This case illustrates a GIST that shows promi-
nent chondro-myxoid differentiation. This was an
indolent tumor amenable to surgical resection. This
unique morphological variant of GIST has not been
previously reported in the literature. The prognosis
and treatment of GIST differs from myxoid
chondrosarcomas, and, thus, it is important to
differentiate between the two tumors.
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